Epilepsy: Novel therapeutic targets

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 2, 2012, Pages 112-117

  Anovadiya, Ashish P ^a   Sanmukhani, Jayesh J ^a   Tripathi, C B ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

AMPA receptor antagonists; mammalian target of rapamycin; metabotropic glutamate receptors; pharmacoresistant epilepsy; protein kinase inhibitors

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 2 AMINO 4 PHOSPHONOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOPYRROLIDINE 2,4 DICARBOXYLATE; ACETAZOLAMIDE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CARBENOXOLONE; CARBOGEN; CARBON DIOXIDE; DIAZEPAM; G PROTEIN COUPLED RECEPTOR; GANAXOLONE; HERBIMYCIN A; K 252A; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROSTEROID; PHENYTOIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG; VID 82925;

ABSENCE; AUTOPHAGY; BRAIN INJURY; CATAMENIAL EPILEPSY; CONVULSION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EMERGENCY CARE; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; FRONTAL LOBE EPILEPSY; HUMAN; INFANTILE SPASM; MYOCLONUS EPILEPSY; NONHUMAN; RECURRENT DISEASE; REVIEW; SEIZURE; TREATMENT RESPONSE; TUBEROUS SCLEROSIS;

EID: 84878810671     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.95505     Document Type: Review

References (48)

1. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilep Behav 2008;12:540-6
2. Rout SK, Kar DM. A review on antiepileptic agents, current research and future prospectus on conventional and traditional drugs. Int J Pharma Sci Rev Res 2010. p. 3
3. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005;25:7724-33
4. Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci 2005;25:5511-20
5. Chen JW, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand Suppl 2007;186:7-15
6. Vizzi ES, Mike A, Tarnawa I. 2,3-benzodiazepines (GYKI 52466 and analogs): Negative allosteric modulators of AMPA receptors. CNS Drug Rev 1996;2:91-126
7. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 2010;51:108-17
8. Pitkänen A, Mathiesen C, Rønn LC, Møller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus: An experimental study in rat. Epilepsy Res 2007;74:45-54
9. Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 1993;15:179-84
10. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol 2008;182:335-60
11. Engel J, Pedley TA, Aicardi J. Epilepsy: A Comprehensive Textbook. Vol. 1-3. Philadelphia: Lippincott-Raven Publishers; 1997
12. Purcell AL, Carew TJ. Tyrosine kinases, synaptic plasticity and memory: Insights from vertebrates and invertebrates. Trends Neurosci 2003; 26:625-30
13. Queiroz CM, Mello LE. Protein tyrosine kinase inhibitors modify kainic acid-induced epileptiform activity and mossy fiber sprouting but do not protect against limbic cell death. Braz J Med Biol Res 2008;41:403-10
14. Salter MW, Kalia LV. Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci 2004;5:317-28
15. Gajda Z, Török R, Horváth Z, Szántai-Kis C, Orfi L, Kéri G, et al. Protein kinase inhibitor as a potential candidate for epilepsy treatment. Epilepsia 2011;52:579-88
16. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81
17. Pellicciari R, Costantino G, Macchiarulo A. Metabotropic glutamate receptors: A structural view point. Pharm Acta Helv 2000;74:231-7
18. Byrnes KR, Loane DJ, Faden AI. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics 2009;6:94-107
19. Sladeczek F, Pin JP, Récasens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 1985;317:717-9
20. Sugiyama H, Ito I, Hirono C. A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 1987;325:531-3
21. Tanabe Y, Masu M, Ishii T, Shigemoto R, Nakanishi S. A family of metabotropic glutamate receptors. Neuron 1992;8:169-79
22. Miller S, Kesslak JP, Romano C, Cotman CW. Roles of metabotropic glutamate receptors in brain plasticity and pathology. Ann N Y Acad Sci 1995;757:460-74
23. Alexander GM, Godwin DW. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res 2006;71:1-22
24. Blümcke I, Becker AJ, Klein C, Scheiwe C, Lie AA, Beck H, et al. Temporal lobe epilepsy associated up-regulation of metabotropic glutamate receptors: Correlated changes in mGluR1 mRNA and protein expression in experimental animals and human patients. J Neuropathol Exp Neurol 2000;59:1-10
25. Durand D, Pampillo M, Caruso C, Lasaga M. Role of metabotropic glutamate receptors in the control of neuroendocrine function. Neuropharmacology 2008;55:577-83
26. Alexander GM, Godwin DW. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res 2006; 71:1-22
27. Watanabe Y, Kaida Y, Fukuhara S, Takechi K, Uehara T, Kamei C. Participation of metabotropic glutamate receptors in pentetrazol-induced kindled seizure. Epilepsia 2011;52:140-50
28. Cao R, Li A, Cho HY.mTOR signaling in epileptogenesis: Too much of a good thing? J Neurosci 2009;29:12372-3
29. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 2010;51:27-36
30. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-Activated protein kinase suppressesprotein synthesis in rat skeletal muscle through down regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002;277:23977-80
31. Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K, et al. A possible linkage between AMP-Activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003;8:65-79
32. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-87
33. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): Pro-And anti-Apoptotic. Cell Death Differ 2002;9:99-100
34. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585-95
35. Shacka JJ, Lu J, Xie ZL, Uchiyama Y, Roth KA, Zhang J. Kainic acid induces early and transient autophagic stress in mouse hippocampus. Neurosci Lett 2007;414:57-60
36. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009;29:6964-72
37. Tolner EA, Hochman DW, Hassinen P, Otáhal J, Gaily E, Haglund MM, et al. Five percent is a potent, fast-acting inhalation anticonvulsant. Epilepsia. Epilepsia 2011;52:104-14
38. Anderson RE, Howard RA, Woodbury DM. Correlation between effects of acute acetazolamide administration to mice on electroshock seizure threshold and maximal electroshock seizure pattern, and on carbonic anhydrase activity in subcellular fractions of brain. Epilepsia 1986;27:504-9
39. Rollins DE, Withrow CD, Woodbury DM. Tissue acid-base balance in acetazolamide-Treated rats. J Pharmacol Exp Ther 1970;174:535-40
40. Xiong ZQ, Stringer JL. Extracellular pH responses in CA1 and the dentate gyrus during electrical stimulation, seizure discharges, and spreading depression. J Neurophysiol 2000;83:3519-24
41. Wang RI, Sonnenschein RR. PH of cerebral cortex during induced convulsions. J Neurophysiol 1955;18:130-7
42. Doherty MJ, Youn C, Gwinn RP, Haltiner AM. Atmospheric pressure and seizure frequency in the epilepsy unit: Preliminary observations. Epilepsia 2007;48:1764-7
43. Ley R. Ventilatory control of heart rate during inhalation of 5% CO2 and types of panic attacks. J Behav Ther Exp Psychiatry 1991; 22:193-201
44. Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K. Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. PLoS One 2007;2:e987
45. Kawato S, Yamada M, Kimoto T. Brain neurosteroids are 4th generation neuromessengers in the brain: Cell biophysical analysis of steroid signal transduction. Adv Biophys 2003;37:1-48
46. Seyfried TN, Todorova MT, Poderycki MJ. Experimental models of multifactorial epilepsies: The EL mouse and mice susceptible to audiogenic seizures. Adv Neurol 1999;79:279-90
47. Murashima YL, Yoshii M. New therapeutic approaches for epilepsies, focusing on reorganization of the GABAA receptor subunits by neurosteroids. Epilepsia 2010;51:131-4
48. Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol 2010;23:170-6